Domestic pharmaceutical firms should explore foreign markets with better R&D capacity

Korean drug makers need to reinforce their research and development (R&D) strategy toward modified new drugs and/or first generics to ensure that firms will be able to survive in the neck-and-neck international competition, said a local expert.

During a local forum organized by the Korea Health Industry Development Institute and Korea Pharmaceutical Manufacturers Association, Lee Yoon-ha, ma...